• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于竞争风险模型预测前列腺癌根治术后患者的癌症特异性生存:一项基于人群的研究。

Predicting Cancer-Specific Survival Among Patients With Prostate Cancer After Radical Prostatectomy Based on the Competing Risk Model: Population-Based Study.

作者信息

Zhou Xianghong, Qiu Shi, Jin Kun, Yuan Qiming, Jin Di, Zhang Zilong, Zheng Xiaonan, Li Jiakun, Wei Qiang, Yang Lu

机构信息

Department of Urology, National Clinical Research Center for Geriatrics and Center of Biomedical Big Data, Institute of Urology, West China Hospital of Sichuan University, Chengdu, China.

出版信息

Front Surg. 2021 Nov 26;8:770169. doi: 10.3389/fsurg.2021.770169. eCollection 2021.

DOI:10.3389/fsurg.2021.770169
PMID:34901145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8660757/
Abstract

We aimed to develop an easy-to-use individual survival prognostication tool based on competing risk analyses to predict the risk of 5-year cancer-specific death after radical prostatectomy for patients with prostate cancer (PCa). We obtained the data from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2016). The main variables obtained included age at diagnosis, marital status, race, pathological extension, regional lymphonode status, prostate specific antigen level, pathological Gleason Score. In order to reveal the independent prognostic factors. The cumulative incidence function was used as the univariable competing risk analyses and The Fine and Gray's proportional subdistribution hazard approach was used as the multivariable competing risk analyses. With these factors, a nomogram and risk stratification based on the nomogram was established. Concordance index (C-index) and calibration curves were used for validation. A total of 95,812 patients were included and divided into training cohort ( = 67,072) and validation cohort ( = 28,740). Seven independent prognostic factors including age, race, marital status, pathological extension, regional lymphonode status, PSA level, and pathological GS were used to construct the nomogram. In the training cohort, the C-index was 0.828 (%95CI, 0.812-0.844), and the C-index was 0.838 (%95CI, 0.813-0.863) in the validation cohort. The results of the cumulative incidence function showed that the discrimination of risk stratification based on nomogram is better than that of the risk stratification system based on D'Amico risk stratification. We successfully developed the first competing risk nomogram to predict the risk of cancer-specific death after surgery for patients with PCa. It has the potential to help clinicians improve post-operative management of patients.

摘要

我们旨在基于竞争风险分析开发一种易于使用的个体生存预后工具,以预测前列腺癌(PCa)患者根治性前列腺切除术后5年癌症特异性死亡风险。我们从监测、流行病学和最终结果(SEER)数据库(2004 - 2016年)获取数据。获得的主要变量包括诊断时年龄、婚姻状况、种族、病理分期、区域淋巴结状态、前列腺特异性抗原水平、病理Gleason评分。为了揭示独立预后因素,累积发病率函数用于单变量竞争风险分析,Fine和Gray的比例子分布风险方法用于多变量竞争风险分析。基于这些因素,建立了列线图和基于列线图的风险分层。一致性指数(C指数)和校准曲线用于验证。共纳入95,812例患者,分为训练队列( = 67,072)和验证队列( = 28,740)。包括年龄、种族、婚姻状况、病理分期、区域淋巴结状态、PSA水平和病理GS在内的七个独立预后因素用于构建列线图。在训练队列中,C指数为0.828(%95CI,0.812 - 0.844),在验证队列中C指数为0.838(%95CI,0.813 - 0.863)。累积发病率函数结果显示,基于列线图的风险分层的辨别能力优于基于D'Amico风险分层的风险分层系统。我们成功开发了首个用于预测PCa患者术后癌症特异性死亡风险的竞争风险列线图。它有可能帮助临床医生改善患者的术后管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/b56c79f1afc6/fsurg-08-770169-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/a05234e21f2a/fsurg-08-770169-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/f54dcac2e2ad/fsurg-08-770169-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/0777df10741a/fsurg-08-770169-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/dda4d200b19d/fsurg-08-770169-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/b56c79f1afc6/fsurg-08-770169-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/a05234e21f2a/fsurg-08-770169-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/f54dcac2e2ad/fsurg-08-770169-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/0777df10741a/fsurg-08-770169-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/dda4d200b19d/fsurg-08-770169-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abae/8660757/b56c79f1afc6/fsurg-08-770169-g0005.jpg

相似文献

1
Predicting Cancer-Specific Survival Among Patients With Prostate Cancer After Radical Prostatectomy Based on the Competing Risk Model: Population-Based Study.基于竞争风险模型预测前列腺癌根治术后患者的癌症特异性生存:一项基于人群的研究。
Front Surg. 2021 Nov 26;8:770169. doi: 10.3389/fsurg.2021.770169. eCollection 2021.
2
Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy.开发并验证了一种术前列线图,用于预测接受根治性前列腺切除术的局部晚期前列腺癌患者的生存情况。
BMC Cancer. 2020 Feb 4;20(1):97. doi: 10.1186/s12885-020-6565-5.
3
A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.一项关于预测当代达米科低风险前列腺癌患者分期升级的新列线图的提议。
World J Urol. 2017 Feb;35(2):189-197. doi: 10.1007/s00345-016-1863-x. Epub 2016 Jun 11.
4
Nomogram to predict cause-specific mortality of patients with rectal adenocarcinoma undergoing surgery: a competing risk analysis.列线图预测接受手术治疗的直肠腺癌患者的特定原因死亡率:竞争风险分析。
BMC Gastroenterol. 2022 Feb 10;22(1):57. doi: 10.1186/s12876-022-02131-1.
5
Nomogram predicting cancer-specific mortality in early-onset rectal cancer: a competing risk analysis.列线图预测早发性直肠癌的癌症特异性死亡率:竞争风险分析。
Int J Colorectal Dis. 2020 May;35(5):795-804. doi: 10.1007/s00384-020-03527-9. Epub 2020 Feb 20.
6
Cardiovascular Outcomes in the Patients With Colorectal Cancer: A Multi-Registry-Based Cohort Study of 197,699 Cases in the Real World.结直肠癌患者的心血管结局:一项基于多登记处的197,699例真实世界病例队列研究。
Front Cardiovasc Med. 2022 Jun 16;9:851833. doi: 10.3389/fcvm.2022.851833. eCollection 2022.
7
Cause-specific mortality of low and selective intermediate-risk prostate cancer patients with active surveillance or watchful waiting.接受主动监测或观察等待的低风险和选择性中度风险前列腺癌患者的特定病因死亡率。
Transl Androl Urol. 2021 Jan;10(1):154-163. doi: 10.21037/tau-20-994.
8
Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.预测前列腺癌根治术后生化复发男性前列腺癌特异性死亡率的列线图
Eur Urol. 2015 Jun;67(6):1160-1167. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.
9
A competing-risk nomogram to predict cause-specific death in elderly patients with colorectal cancer after surgery (especially for colon cancer).用于预测老年结直肠癌(尤其是结肠癌)术后患者特定原因死亡的竞争风险列线图。
World J Surg Oncol. 2020 Feb 4;18(1):30. doi: 10.1186/s12957-020-1805-3.
10
Developing and validating a novel nomogram used a competing-risks model for predicting the prognosis of primary fallopian tube carcinoma: a retrospective study based on the SEER database.开发并验证一种用于预测原发性输卵管癌预后的新型列线图,该列线图采用竞争风险模型:一项基于监测、流行病学和最终结果(SEER)数据库的回顾性研究。
Ann Transl Med. 2021 Mar;9(5):378. doi: 10.21037/atm-20-5398.

引用本文的文献

1
Integrating Ga-PSMA-11 PET/CT with Clinical Risk Factors for Enhanced Prostate Cancer Progression Prediction.整合镓-PSMA-11 PET/CT与临床风险因素以增强前列腺癌进展预测
Cancers (Basel). 2025 Jul 9;17(14):2285. doi: 10.3390/cancers17142285.
2
Improving Outcomes in Urological Surgery for the Elderly: Strategies for Optimization and Risk Reduction.改善老年泌尿外科手术的治疗效果:优化与降低风险的策略
Curr Urol Rep. 2025 Jun 30;26(1):54. doi: 10.1007/s11934-025-01284-2.
3
Real-world comparative outcomes and toxicities after definitive radiotherapy using proton beam therapy versus intensity-modulated radiation therapy for prostate cancer: a retrospective, single-institutional analysis.

本文引用的文献

1
Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.人表皮生长因子受体 2 阳性乳腺癌患者的临床特征和生存预测列线图的建立。
ESMO Open. 2021 Aug;6(4):100232. doi: 10.1016/j.esmoop.2021.100232. Epub 2021 Aug 13.
2
A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy.一种新的基于免疫相关基因的预后标志物,用于预测根治性前列腺切除术后前列腺癌患者的生化复发。
Cancer Immunol Immunother. 2021 Dec;70(12):3587-3602. doi: 10.1007/s00262-021-02923-6. Epub 2021 May 2.
3
质子束治疗与调强放射治疗用于前列腺癌根治性放疗后的真实世界比较结局和毒性:一项回顾性单机构分析
J Radiat Res. 2025 Jan 22;66(1):39-51. doi: 10.1093/jrr/rrae065.
4
Extra-prostatic extension grading system: correlation with MRI features and integration of capsular enhancement sign for "enhanced" detection of T3a lesions.前列腺外延伸分级系统:与 MRI 特征的相关性以及包膜增强征象的整合,用于“增强”检测 T3a 病变。
Br J Radiol. 2024 May 7;97(1157):971-979. doi: 10.1093/bjr/tqae065.
5
The survival benefit of different lymph node yields in radical prostatectomy for pN1M0 prostate cancer patients: Implications from a population-based study.根治性前列腺切除术治疗pN1M0前列腺癌患者时不同淋巴结清扫数量的生存获益:一项基于人群研究的启示
Front Oncol. 2022 Aug 11;12:953069. doi: 10.3389/fonc.2022.953069. eCollection 2022.
6
The Dilemma of Misclassification Rates in Senior Patients With Prostate Cancer, Who Were Treated With Robot-Assisted Radical Prostatectomy: Implications for Patient Counseling and Diagnostics.接受机器人辅助根治性前列腺切除术的老年前列腺癌患者分类错误率的困境:对患者咨询和诊断的影响
Front Surg. 2022 Feb 16;9:838477. doi: 10.3389/fsurg.2022.838477. eCollection 2022.
Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in GaPSMA-11 PET images of patients with primary prostate cancer.
在原发性前列腺癌患者的GaPSMA-11 PET图像中发现隐匿性——视觉上不可检测的前列腺内肿瘤病变的患病率、特征及基于放射组学特征的检测
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1987-1997. doi: 10.1007/s00259-020-05111-3. Epub 2020 Nov 18.
4
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌指南-2020 版更新。第 1 部分:筛查、诊断和以治愈为目的的局部治疗。
Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7.
5
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌诊治指南。第二部分-2020 年更新:复发性和转移性前列腺癌的治疗。
Eur Urol. 2021 Feb;79(2):263-282. doi: 10.1016/j.eururo.2020.09.046. Epub 2020 Oct 7.
6
Development of an Individualized Prediction Calculator for the Benefit of Postoperative Radiotherapy in Patients with Surgically Resected De Novo Stage IV Breast Cancer.为接受手术切除的初治IV期乳腺癌患者术后放疗获益开发个体化预测计算器
Cancers (Basel). 2020 Jul 29;12(8):2103. doi: 10.3390/cancers12082103.
7
Genomic Profiling of Prostate Cancers from Men with African and European Ancestry.非洲裔和欧洲裔男性前列腺癌的基因组分析。
Clin Cancer Res. 2020 Sep 1;26(17):4651-4660. doi: 10.1158/1078-0432.CCR-19-4112. Epub 2020 Jul 10.
8
A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis.预测低级别子宫内膜间质肉瘤患者总生存期的列线图:基于人群的分析。
Cancer Commun (Lond). 2020 Jul;40(7):301-312. doi: 10.1002/cac2.12067. Epub 2020 Jun 18.
9
Clinical Applications of Molecular Biomarkers in Prostate Cancer.分子生物标志物在前列腺癌中的临床应用
Cancers (Basel). 2020 Jun 12;12(6):1550. doi: 10.3390/cancers12061550.
10
Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients.建立一个自噬相关基因表达谱,用于预测前列腺癌患者的预后。
J Transl Med. 2020 Apr 7;18(1):160. doi: 10.1186/s12967-020-02323-x.